Pharmacy Times

AUGUST 7, 2025

Methods Patients aged 18 to 59 years with t-AML or AML-MRC treated with CPX-351 or 7+3 as induction chemotherapy between 2015 and 2022 at 3 National Cancer Institute–designated cancer centers were included. 4 These findings led to the 2017 FDA approval of CPX-351 for adult patients with t-AML or AML-MRC.

Chemotherapy

European Pharmaceutical Review

NOVEMBER 19, 2024

.” In a Q&A with EPR last year, Hoppin and Ratio’s Director, President and Chief Scientific Officer, Dr John Babich, described that “there is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies.”

Chemotherapy

The Thyroid Pharmacist

AUGUST 1, 2025

Thyroid Medication Safety During Pregnancy and Breastfeeding Thyroid medications are known to be safe during pregnancy and are rated by the FDA as a category A drug for pregnancy, which means there is no evidence of harm to the fetus. Updated 2022 Jul 25]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Breastfeeding.

Health and Personal Care Stores

Pharmacy Times

JUNE 6, 2025

According to the study authors, it represents the sixth leading cause of cancer-related mortality in the US and was the fourth most commonly diagnosed cancer worldwide in 2022. 1 Image credit: sinhyu | stock.adobe.com HCC is the most prevalent type of primary liver cancer in adults.

Compounding Pharmacies

pharmaphorum

NOVEMBER 28, 2021

The three-year phase 2 trial will be carried out by researchers at Leeds University led by professor of clinical oncology and neuro-oncology Susan Short, and see if adding Sativex (nabiximols) to standard chemotherapy for recurrent glioblastoma can extend survival. Jazz acquired rights to Sativex when it completed its $7.2

Chemotherapy

pharmaphorum

APRIL 19, 2022

AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if it will approve their HER2 drug Enhertu for non-small cell lung cancer (NSCLC) and add to its current uses in breast and gastric cancer. The post FDA starts speedy review of Enhertu in lung cancer appeared first on.

FDA

Pharmaceutical Technology

SEPTEMBER 13, 2022

Once patients become resistant to standard of care (SOC) endocrine-based therapies and CDK 4/6 inhibitors, the prognosis is poor, with treatment options limited to single-agent chemotherapies. Findings of the study, reported at the ESMO Congress 2022, demonstrated a 3.2-month months) versus physicians’ choice chemotherapy (11.2

Chemotherapy

Pharmaceutical Technology

MARCH 30, 2023

The European Commission (EC) has granted approval for Regeneron Pharmaceuticals’ Libtayo (cemiplimab), along with platinum-based chemotherapy, as the first-line treatment for PD-L1 expression positive advanced non-small cell lung cancer (NSCLC) in adult patients.

Chemotherapy

STAT

NOVEMBER 30, 2023

Food and Drug Administration approval for advanced ovarian cancer in 2022. Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. Continue to STAT+ to read the full story…

Compounding

Pharmaceutical Technology

FEBRUARY 26, 2023

While the French MaaT Pharma has submitted further information to the FDA, its trial remains on hold. In November 2022, Ferring Pharmaceuticals’s Rebyota became the first FDA-approved microbiome-based therapeutic to treat recurrent CDI. But the approval came through after an FDA Advisory Committee meeting. with placebo.

FDA

European Pharmaceutical Review

MAY 4, 2023

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. They are not US Food and Drug Administration (FDA)-approved for these patients due to the lack of benefit. 2022; 10(1). 2022; 24(2): 89 – 97. Cancer Ther.

Immunization

Pharmaceutical Technology

APRIL 26, 2023

The US Food and Drug Administration (FDA) has granted orphan drug designation to IN8bio’s INB-400 and INB-410 to treat a range of malignant gliomas, including newly diagnosed glioblastoma multiforme (GBM). This marks the first-ever designation for genetically modified gamma-delta T cell therapies.

FDA

Pharmaceutical Technology

MARCH 30, 2023

On March 27, MSD announced that the combined use of Keytruda with chemotherapy significantly improved progression-free survival versus the chemotherapy alone, as a first-line therapy for advanced or recurrent endometrial carcinoma. In 2022, the company reported Keytuda sales of $20.9 billion in its FY 2022 results.

Chemotherapy

Pharmaceutical Technology

MARCH 6, 2023

Patients in the US and EU with recurrent or metastatic nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell carcinoma (HNSCC), are mostly treated with a combination of chemotherapy agents in the frontline setting, such as cisplatin + gemcitabine. months for the chemotherapy arm (hazard ratio [HR]: 0.52).

Chemotherapy

Pharmaceutical Technology

JUNE 4, 2023

Patients with resectable stage II, IIIA, and IIIB (T3-4N2) disease of both squamous and non-squamous histology were randomized to receive neoadjuvant Keytruda with platinum-based chemotherapy followed by adjuvant Keytruda, or placebo with platinum-based chemotherapy followed by placebo. At a median duration of follow-up of 25.2

Chemotherapy

European Pharmaceutical Review

OCTOBER 19, 2023

The development of novel radiotherapeutics ushered in a new era in targeted treatment 1 for cancer, with two separate radiotherapeutic approvals in Europe and the US, in 2018 and 2022. How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy?

Chemotherapy

pharmaphorum

DECEMBER 5, 2022

Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case, lutetium-177) – to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.

Chemotherapy

Pharmaceutical Technology

MARCH 23, 2023

The drug is currently licensed in combination with chemotherapy for patients with classical Hodgkin lymphoma, both as frontline therapy and for those at risk of progressing or having progressed following stem cell transplantation. Seagen generated almost $2 billion in revenue in 2022, an increase approaching 25% from 2021.

Chemotherapy

pharmaphorum

JULY 19, 2022

China’s Simcere Pharmaceutical has been granted approval in its home market for Cosela, a drug designed to limit the side effects of cancer chemotherapy, partnered with US biotech G1 Therapeutics. Simcere said that the number of new cancer patients requiring chemotherapy in China is expected to reach 4.2

Chemotherapy

pharmaphorum

NOVEMBER 29, 2022

During the ‘Next-Generation Cytokine Therapy’ session at the Society for Immunotherapy of Cancer’s (SITC) 2022 annual meeting, Dr A Naing (University of Texas MD Anderson Cancer Center) presented the results from two cohorts of patients from the phase 2a clinical trial NIT-110, with relapsed/refractory (r/r) gastrointestinal indications.

Immunization

pharmaphorum

OCTOBER 3, 2022

Indeed, in the US, the FDA has recently declined approval of Lilly’s sintilimab (Tyvyt), driven in part by a vote 14-1 against approval by the Oncologic Drugs Advisory Committee, owing to the availability of China-only data1. online] Available at: <[link] [Accessed 13 April 2022]. References. Food and Drug Administration.

Chemotherapy

PQA

MAY 30, 2024

More than 120 FDA-approved OAMs were used in clinical practice in 2022, and OAMs represent more than one-third of cancer medications in the development pipeline. neoadjuvant or adjuvant chemotherapy vs. adjuvant endocrine therapy for the prevention of recurrence). Here are four key challenges to standardized measurement.

Chemotherapy

European Pharmaceutical Review

JANUARY 3, 2023

Arm A participants will be treated with Cisplatin-based chemotherapy without receiving SENS-401. Arm B participants will receive 43.5mg of oral SENS-401 one week prior to getting cisplatin treatment, during the whole duration of the chemotherapy treatment and four weeks after receiving the last cycle of cisplatin.

Chemotherapy

European Pharmaceutical Review

AUGUST 31, 2023

By reaching cancer cells that have already spread throughout the body, a targeted radiopharmaceutical treatment offers an alternative for patients with advanced cancer when standard lines of treatment, such as chemotherapy, have failed. FDA approves new treatment for certain digestive tract cancers [Internet]. 2022; Vol.

Hospitals

Hospital Pharmacy Europe

NOVEMBER 6, 2023

Adagrasib is a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.

Hospitals

The Checkup by Singlecare

DECEMBER 13, 2023

Antiemetics may also reduce radiation-associated or chemotherapy-induced nausea resulting from cancer treatment. Kaopectate tablet and liquid suspension Bismuth subsalicylate is FDA-approved for treating nausea and vomiting. Antiemetic medications , StatPearls (2022).

Dosage

European Pharmaceutical Review

JULY 18, 2024

1,2 This is especially important in forms of cancer where chemotherapy remains the main treatment option. Because ADCs offer a good way to specifically deliver an effective treatment to tumour systems, this could be an improvement on the systemic impact of chemotherapy. 2022; 7(93) Maecker et al. References Fu et al.

Chemotherapy

pharmaphorum

OCTOBER 19, 2022

Zanidatamab is an HER2-targeted bispecific antibody with multiple novel mechanisms of action that has demonstrated ‘compelling’ anti-tumour activity in several HER2-expressing cancers, operating both as a monotherapy and in combination with chemotherapy and other agents. The transaction is expected to close within the 2022 calendar year.

Chemotherapy

pharmaphorum

JUNE 12, 2022

The new data comes just after bluebird bio’s gene therapy for TDT – betibeglogene autotemcel (beti-cel) – was recommended for approval by an FDA advisory committee on Friday, setting it up to possibly reach the US market later this year.

Chemotherapy

Pharmaceutical Technology

JUNE 16, 2023

In 2021, as part of the same Keynote-811 trial, the US Food and Drug Administration (FDA) granted accelerated approval to Keytruda for treating locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma, in combination with trastuzumab and chemotherapy containing fluoropyrimidin and platinum.

Chemotherapy

Roots Analysis

OCTOBER 4, 2023

During the research, I noticed a significant increase in the number of FDA approvals for bispecific antibodies in recent years. In fact, six bispecific antibodies have been approved in 2022. I, recently, worked on a market research report, titled Bispecific Antibodies Market , 2023-2035.

Chemotherapy

The Checkup by Singlecare

DECEMBER 29, 2023

Safety measures while using CoQ10 What are the FDA warnings about CoQ10? The Food and Drug Administration (FDA) has not issued any warnings about CoQ10. It is available over the counter, so the FDA has determined that it’s safe to use without medical supervision. Who should never take CoQ10? Who should use caution with CoQ10?

FDA

European Pharmaceutical Review

DECEMBER 27, 2023

Bridging therapy has been shown to correlate with an inferior response to CAR T-cell therapy due to both progression of the chemotherapy-refractory malignant disease during the manufacturing period and increased toxicity. FDA; 2022 [cited 2023 Mar]. 2021;3(S1):6–10. Center for Biologics Evaluation and Research.

Adverse Reactions

The Thyroid Pharmacist

SEPTEMBER 20, 2024

Plecanatide : This is one of the newest medications for IBS-C that has been approved by the FDA. Tenapanor : Tenapanor was approved by the FDA in September of 2019 for IBS-C. [45] As the intestines are made of smooth muscles, a reduction in the action of these muscles can slow down digestion and cause constipation. 2009;2009:529802.

Health and Personal Care Stores

The Checkup by Singlecare

MARCH 23, 2023

Moreover, a different study published in 2022 found that products with a high THC-to-CBD ratio were more effective at decreasing chronic pain than either agent alone, suggesting that THC can help in pain management by producing euphoria. They are prescribed to increase appetite in patients receiving chemotherapy.

Controlled Substances

Roots Analysis

JANUARY 22, 2024

Currently, several conventional approaches, such as surgery, radiation therapy, chemotherapy and immunotherapy are available for treating cancer. Owing to this, regulatory authorities, such as the US FDA are encouraging more research and development initiatives in the domain of oncology precision medicine.

Medical Records

ISPE

MAY 10, 2023

Mexican Governor: Cancer Children Given Water Instead of Chemotherapy.” Proceedings of Medical Informatics, Europe, Nice, 2022: 755–59. SPuMoNI is particularly timely because blockchain has been proposed to become “a new digital service infrastructure” for Europe. 30 June 2016. link] 6 BBC News. Published 19 January 2017. Cai, and X.

Chemotherapy